pfizer inc (PFE:Frankfurt)

Executive Profile*

Background*

Prof. Mikael Dolste, Ph.D. has been the President of Worldwide Research and Development of Pfizer Inc. since December 2010. Prof. Dolsten is a Partner at OrbiMed Advisors, L.L.C. Prof. Dolsten serves as Head of Corporate Division Pharma Research/Discovery at Boehringer Ingelheim with responsibility for approximately 1400 discovery scientists and world-wide research in respiratory, immunology/inflammation, metabolic disease, CNS/pain, oncology and cardiovascular therapies. ... Prof. Dolsten has spent approximately seventeen years in the pharmaceutical Industry. He has held various senior R&D management positions including: Head of Preclinical Research Oncology/Immunology at Pharmacia & Upjohn, Lund, and Head of Preclinical R&D, Vice President of Respiratory and Inflammation at Astra Draco, Lund. Before joining Boehringer Ingelheim in 2003, Prof. Dolsten was responsible for integrating several areas of AstraZeneca Discovery post-merger; he also served as Global Vice President/Head of Cardiovascular/Metabolic & Gastrointestinal Discovery at AstraZeneca, directing the work of over 750 scientists at research sites in Sweden and the UK. He is a Member of MDL Scientific Advisory Board at Elsevier B.V., and served as Director of Receptos, Inc. Prof. Dolsten served as Associate Professor in 1989 and Adjunct Professor in Cell and Molecular Biology in 1996 at Lund University. Prof. Dolsten is an author of some 150 scientific articles and book chapters. Prof. Dolsten earned his Ph.D. in tumor immunology and M.D. from the University of Lund in Sweden. He also studied virology and cell biology at the Weizmann Institute in Israel.

Report Data Issue

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Recently Viewed
PFE:GR	€22.25 EUR	+0.276

COMPETITOR COMPENSATION